Drug Database
TA

tamsulosin (tamsulosin WOWTAB / Harnal D)

✓ Approved

Astellas Pharma · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namestamsulosin WOWTAB, Harnal D
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Astellas Pharma

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedInternational journal of clinical and experimental pathology2026-07-17

Tamsulosin versus placebo for medical expulsive therapy in ureteral calculi: a systematic review and meta-analysis of randomized controlled trials.

Yang Jinxin J, Yang Jin J, Zhang Hanchao H, Hu Haifeng H et al.

Ureteral calculi are a common cause of emergency department visits worldwide. Although small stones often pass spontaneously, medical expulsive therapy is frequently used to facilitate stone clearance and reduce the need for surgical intervention. Tamsulosin, an α1-adrenergic receptor antagonist, is commonly prescribed for this purpose, but its efficacy compared with placebo remains uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials comparing tamsulosin with placebo in patients with ureteral calculi. A comprehensive search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed from database inception through April 2025. The primary outcome was the stone expulsion rate, and secondary outcomes included time to expulsion and the incidence of adverse events. Pooled estimates were calculated as risk ratios or mean differences with 95 percent confidence intervals, using a random-effects model. A total of 42 randomized controlled trials involving 7,117 patients met the inclusion criteria. Compared with placebo, tamsulosin significantly increased the stone expulsion rate (risk ratio 1.42, 95 percent confidence interval 1.29 to 1.56, P < 0.001) and shortened the time to expulsion by an average of 3.04 days (95 percent confidence interval 2.28 to 3.81 days, P < 0.00001). The overall incidence of adverse events did not differ significantly between groups, although subgroup analysis indicated a lower risk of moderate to severe complications with tamsulosin (risk ratio 0.35, 95 percent confidence interval 0.22 to 0.98, P < 0.0001). Substantial heterogeneity was observed across outcomes. In conclusion, tamsulosin improves stone expulsion and reduces clearance time without increasing overall adverse events. However, given the considerable heterogeneity among studies, these findings should be interpreted with caution. Further high-quality, large-scale trials are needed to confirm the benefits of tamsulosin and to identify patient subgroups most likely to benefit from therapy.

PMID 42466212
Read full article →
PubMedInternational journal of pharmaceutics2026-07-17

A structure dosage form approach for solubility and dissolution rate enhancement.

Zuo Xianghao X, Jain Uday U, Deng Feihuang F, Hui Ho-Wah HW et al.

Despite various attempts at solubility enhancement and advances in formulation technologies, improving the bioavailability of poorly water-soluble compounds remains a significant challenge. Melt extrusion deposition (MED®) 3D printing is an additive manufacturing technology developed specifically for pharmaceutical applications to produce dosage forms with complex internal and external geometrical structures. This technology provides novel solutions and unique opportunities for enhancing the bioavailability of poorly soluble compounds through structurally engineered tablets and supports the development of patient-centric medications tailored to meet diverse clinical needs. This study describes the use of MED® technology to formulate a poorly water-soluble model compound, enhance its solubility, and modulate its release profile to achieve immediate release (IR), extended release (ER), and extended-plus-delayed release (ER + DR). After the model compound was formulated as an amorphous solid dispersion (ASD), the solubility in distilled water increased to around 60 μg/mL, representing up to a 4-fold increase relative to its thermodynamic solubility (∼15 μg/mL). Utilizing the same ASD drug-core formulation, two distinct 3D-printed tablet structures were designed and fabricated: a mesh structure for an IR tablet and a multi-compartment structure with variable-thickness delayed-release layers for an ER + DR tablet. These designs enabled tailored release profiles for the poorly water-soluble model compound. This structure-driven approach via MED® 3D printing enables both solubility enhancement and precise release modulation for poorly water-soluble drugs, thereby providing a new pathway for the rational design and efficient development of tablet dosage forms.

PMID 42462914
Read full article →
PubMedAnnales de chirurgie plastique et esthetique2026-07-17

Immediate breast reconstruction versus delayed immediate breast reconstruction: A Strasbourg experience retrospective study.

Deltonne S S, Kara P P, Huttin C C, Bodin F F

Delayed-immediate breast reconstruction (DIBR) using a temporary tissue expander is commonly recommended when post-mastectomy radiotherapy (PMRT) is anticipated, with the aim of optimizing aesthetic outcomes. However, the actual benefit of tissue expanders compared with immediate breast reconstruction (IBR) remains debated. We conducted a retrospective monocentric observational study including patients who underwent curative or prophylactic mastectomy followed by IBR or DIBR between January 2019 and December 2023. Reconstruction techniques included definitive implants, tissue expanders, and autologous flaps. The primary endpoint was aesthetic outcome assessed on standardized postoperative photographs using the Vrieling scale by six blinded plastic surgeons. Secondary endpoints included patient-reported outcomes using the BREAST-Q questionnaire, number of surgical procedures, capsular contracture (Baker classification), and postoperative complications (Clavien-Dindo). Multivariate analyses were performed to account for confounders, including radiotherapy. A total of 149 patients (192 reconstructions) were included (160 IBR, 32 DIBR). No significant difference in aesthetic outcomes was observed between IBR and DIBR overall, nor within implant-based or flap-based subgroups. BREAST-Q scores were comparable between groups across psychosocial, sexual well-being, and breast satisfaction domains, although chest physical well-being was significantly lower in the DIBR group (P=0.03). Patients undergoing flap reconstruction reported higher breast satisfaction than those with implant-based reconstruction (P<0.001). DIBR required significantly more surgical procedures than IBR (2.3 vs. 1.6; P<0.001). Radiotherapy negatively impacted patient-reported satisfaction but did not significantly influence aesthetic scores or complication rates between groups. Among patients who completed reconstruction, DIBR did not confer a measurable aesthetic advantage over IBR, while requiring more surgical procedures and being associated with lower chest physical well-being. Immediate reconstruction may be sufficient in selected patients, even when radiotherapy is required.

PMID 42463398
Read full article →
PubMedJournal of orthopaedic trauma2026-07-17

Carpal Tunnel Release: Technical Considerations for the Orthopaedic Trauma Surgeon.

Coscia Atticus A, Weinerman Jonathan J, Hake Mark M, Lawton Jeffrey J

Emergent carpal tunnel release is indicated for acute carpal tunnel syndrome, most commonly secondary to distal radius fracture and may be performed in the setting of forearm/hand compartment syndrome along with forearm and/or hand fasciotomies if median nerve compression is suspected. Carpal tunnel release can safely and efficiently be performed concurrent to fracture fixation and/or compartment release, generally with excellent results. This abstract is intended to serve as a succinct review for orthopaedic traumatologists who do not routinely perform carpal tunnel release on an elective basis, describing the relevant anatomy, structures at risk, and an incision design required to successfully perform open carpal tunnel release.

PMID 42466774
Read full article →
PubMedBMC oral health2026-07-17

Implant stability following septal expansion in immediate mandibular molars: a pilot randomized clinical trial comparing piezoelectric surgery and osseodensification.

Hassan Hussien El H HEH, Khlalil Abdelaziz F AF, Metawie Dina M N DMN

Immediate implant placement (IIP) in mandibular molars is challenged by wide extraction sockets and limited septal bone support. This pilot feasibility randomized clinical trial evaluated primary and secondary implant stability following septal expansion using piezoelectric surgery (PISP) compared with osseodensification (OD) using Densah® burs. Twenty patients were randomly allocated (1:1) to either PISP group or OD group for immediate mandibular molar implant placement. The primary outcome was implant stability quotient (ISQ), measured immediately and at 3 months. Secondary outcomes included insertion torque, osteotomy preparation time, and postoperative pain assessed using a visual analogue scale (VAS) during the first postoperative week. Normality was evaluated using Shapiro-Wilk tests and Q-Q plots. Between-group comparisons were performed using independent t-tests, while VAS scores were analyzed using Mann-Whitney U and Friedman tests (α = 0.05). No statistically significant differences were observed between groups in primary or secondary ISQ (p > 0.05). Both groups demonstrated a significant increase in ISQ at 3 months compared with baseline (p < 0.001). The mean insertion torque was significantly higher in the PISP group (40.33 ± 3.24 Ncm; p = 0.004) compared to the OD group (35.00 ± 3.53 Ncm). Osteotomy preparation time was significantly longer in the PISP group (9.00 ± 0.94 min) than in the OD group (6.00 ± 0.82 min) (p < 0.001). Postoperative VAS pain scores were significantly lower in the PISP group throughout the first week (p < 0.05). All implants achieved clinical stability with no intra- or postoperative complications. The preliminary findings of this pilot feasibility trial demonstrated that PISP achieves comparable biomechanical stability to OD, establishing its clinical feasibility for immediate molar implant placement in anatomically complex posterior regions. NCT06957860 ; registered May 5, 2025.

PMID 42464273
Read full article →
PubMedWater research2026-07-17

Quantifying turbulence-burst-induced PFASs release across the sediment-water interface: 3D coupled computation of the boundary layer zone.

Guo Peng P, Hua Zulin Z, Wang Peng P, Yu Liang L

Turbulence bursting induced by hydrodynamic forcing within the boundary layer is a dominant driver of PFASs release and transport. Existing models rarely account for the vortex structures generated during bursting events, leading to incomplete quantification of burst-driven release processes. To address this gap, a coupled numerical model was developed to simulate PFASs release from sediments under turbulence-burst forcing, including PFASs transport through pore water, and subsequent transfer across the sediment-water interface into the overlying water. The model employs a Detached Eddy Simulation approach to resolve boundary-layer vortex structures and incorporates a hydrodynamic effect factor to enhance PFASs release responsiveness. Velocity threshold, determined by comparing release depths, was used to define the effective range. By jointly resolving the overlying water and pore water domains, the model provides a more accurate characterisation of boundary-layer processes. The simulations reproduce pore-water PFASs gradients and align with measured residual sediment concentrations (R² = 0.84). The model captures the relationship between PFASs release and vortex intensity under three flow situations. Notably, short-chain PFASs exhibit greater downward penetration under high-intensity vortical structures. Localised high-concentration enrichment zones were observed within the sediments under weak vortex-driven conditions. The results demonstrate that vortex evolution during turbulence bursting significantly influences PFASs release dynamics. This model provides a valuable framework for understanding the micro-scale processes governing PFASs release at the sediment-water interface.

PMID 42462652
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin